Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ribaxamase - Theriva Biologics

Next Previous
X
Search
Drug Profile

Ribaxamase - Theriva Biologics

Alternative Names: Bacillus licheniformis isoenzyme; Kymerase; P3A; SYN 007; SYN-004 - Theriva Biologics

Latest Information Update: 16 Apr 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Ipsat Therapies
  • Developer Theriva Biologics
  • Class Aminohydrolases; Antibacterials; Irritable bowel syndrome therapies
  • Mechanism of Action Beta lactamase replacements; Gastrointestinal microbiome modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Clostridium difficile infections
  • Phase I/II Graft-versus-host disease
  • Discontinued Irritable bowel syndrome

Most Recent Events

  • 16 Apr 2024 Discontinued - Preclinical for Irritable bowel syndrome (Prevention) in USA (unspecified route) before December 2023
  • 31 Dec 2023 Ribaxamase is available for licensing as of 31 Dec 2023. https://therivabio.com/contact/
  • 28 Nov 2023 No recent reports of development identified for preclinical development in Irritable-bowel-syndrome(Prevention) in USA

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top